Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Medical and cosmopolitan professional specialised in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practise contributing to bring innovative science and diplomacy for global health. Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe. Speaking French, English, Russian, Italian, Czech, Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies (Director of R&D for new delivery platforms focused on children and elderly) for various therapeutic areas for adults and children including neurodegenerative diseases, infectious diseases, metabolic diseases and orphan indications. Active member of French immunology society (SFI) administrative board and several international academic societies (focus on innovation of R&D reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic, tackle problem of resistance for antimicrobials, antimalarial, antivirals etc). Member of advisory Health concern (India) and think tank group in order to attract attention to role of immunology, personalised and preventive medicine and accurate diagnostic and global cooperation in this area. Years of expertise to work globally within Europe, USA but recently more focused on BRICS - Asia (India in Particular) as a Medical advisor bringing new innovative concepts alive and getting them endorsed.
A vaccine is a biological preparation that improves immunity to a particular microorganism. Accurate diagnostic and surveillance with better understanding of genetic and immunologic background of host specific response and pathogen evolution drives adapted vaccine research. AMR (antimicrobial) resistance is regarded nowdays as a major threat to global public health. The issue is receiving high-level political attention (G7 summit and upcoming G20 for first time). Pandemics, drug resistance and neglected diseases framing health as a “global security issue”. WHO drawn up a list to promote research and development (R&D) of new antibiotics (27th Feb 2017) underlining gram-negative bacteria. Although initially omitted from the list, tuberculosis and latent tuberculosis represent still a major issue to tackle. XDR tuberculosis has evolved in several tuberculosis endemic countries to drug incurable or programmatically incurable tuberculosis. BCG vaccine successfully helped to interrupt transmission cycle and along with antibiotic discovery to decrease mortality. However, its efficacy remains controversial. HIV/AIDS has known link with tuberculosis but other risk factors have also emerged in recent years as important determinants of the TB epidemic, one of which is diabetes mellitus. Risk or new emerging and re-emerging pathogens originated from animals after having crossed the species barrier (e.g Ebola) and re-appearance of “old diseases” like pertussis, measles and known limitations of drugs underline need for innovative vaccines as highly potent tool to tackle resistance and valuable alternative from long term perspective being clearly recognized as a major tool for public health.